Share your videos with the world

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, reported that The New England Journal of Medicine today published results from Cohort B of The PARTNER Trial, which studied the Edwards SAPIEN transcatheter heart valve for the treatment of severe aortic stenosis. The results of the trial successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/44227/